Zollner, Thomas M <br/><br/>
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.  [electronic resource] 

 -  The Journal of clinical investigation  Mar 2002 
 - 671-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0021-9738 
<br/><br/><label>Standard No.: </label>10.1172/JCI12736  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylcysteine--analogs & derivatives<br/>Animals<br/>Antigens, CD--metabolism<br/>Antigens, Differentiation, T-Lymphocyte--metabolism<br/>Bacterial Toxins<br/>Cysteine Endopeptidases<br/>Cysteine Proteinase Inhibitors--pharmacology<br/>DNA--drug effects<br/>Disease Models, Animal<br/>Enterotoxins--immunology<br/>HLA-DR Antigens--metabolism<br/>Humans<br/>Lectins, C-Type<br/>Lymphocyte Activation--drug effects<br/>Mice<br/>Mice, SCID<br/>Multienzyme Complexes--antagonists & inhibitors<br/>NF-kappa B--metabolism<br/>Proteasome Endopeptidase Complex<br/>Psoriasis--drug therapy<br/>Receptors, Interleukin-2--metabolism<br/>Skin Transplantation--immunology<br/>Superantigens--metabolism<br/>T-Lymphocytes--drug effects<br/>Transplantation, Heterologous